Offer - Urjas Oil for just ₹ 1
.
Tecentriq (Atezolizumab) is a monoclonal antibody that belongs to a class of immune checkpoint inhibitors. It is designed to block the programmed death-ligand 1 (PD-L1) protein, enhancing the immune system's ability to detect and destroy cancer cells. Tecentriq is used in the treatment of various advanced cancers, including lung, liver, breast, and bladder cancers.
Indications:
Non-Small Cell Lung Cancer (NSCLC):
As a single agent or in combination with chemotherapy for advanced or metastatic cases.
Small Cell Lung Cancer (SCLC):
In combination with chemotherapy as first-line treatment for extensive-stage disease.
Triple-Negative Breast Cancer (TNBC):
In combination with nab-paclitaxel for PD-L1-positive, unresectable locally advanced, or metastatic disease.
Hepatocellular Carcinoma (HCC):
In combination with bevacizumab for patients with no prior systemic therapy.
Urothelial Carcinoma:
For patients with advanced or metastatic disease who are ineligible for cisplatin-containing chemotherapy.
Tecentriq works by inhibiting the PD-L1 protein on cancer cells, which normally binds to the PD-1 receptor on T-cells to suppress their activity. By blocking this interaction, Tecentriq restores T-cell activity, enabling the immune system to recognize and attack cancer cells.
Common Side Effects: Fatigue, Nausea, Diarrhea, Decreased appetite, Rash.
Serious Side Effects:
Immune-Related Reactions: Pneumonitis (lung inflammation), Hepatitis (liver inflammation), Colitis (intestinal inflammation), Endocrinopathies (e.g., hypothyroidism, adrenal insufficiency).
Infusion Reactions: Fever, chills, and shortness of breath during infusion.
Severe Infections: Increased risk of infections due to immune modulation.
Standard Dose for Adults:
840 mg IV every 2 weeks, or
1,200 mg IV every 3 weeks, or
1,680 mg IV every 4 weeks.
Administration Tips:
Administer as an intravenous infusion over 60 minutes.
If well-tolerated, subsequent infusions can be reduced to 30 minutes.
Ensure pre-treatment screening for liver function, PD-L1 status, and overall patient health.
Tecentriq 840mg Injection is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
Based on research, the following side effects have been observed when Tecentriq 840mg Injection is used -
Severe
Moderate
Is the use of Tecentriq 840mg Injection safe for pregnant women?
Is the use of Tecentriq 840mg Injection safe during breastfeeding?
What is the effect of Tecentriq 840mg Injection on the Kidneys?
What is the effect of Tecentriq 840mg Injection on the Liver?
What is the effect of Tecentriq 840mg Injection on the Heart?
Tecentriq 840mg Injection should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
If you are suffering from any of the following diseases, you should not take Tecentriq 840mg Injection unless your doctor advises you to do so -
Is this Tecentriq 840mg Injection habit forming or addictive?
Is it safe to drive or operate heavy machinery when consuming?
Is it safe?
Is it able to treat mental disorders?
Interaction between Food and Tecentriq 840mg Injection
Interaction between Alcohol and Tecentriq 840mg Injection
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Tecentriq® (atezolizumab)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 198-200
